Barclays Maintains Overweight on Orchestra BioMed Hldgs, Raises Price Target to $13

Benzinga Newsdesk www.benzinga.com Positive 87.8%

Neg 0% Neu 0% Pos 87.8%

Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $12 to $13.